Adjuvant Capital
Adjuvant Capital is a life sciences investment fund that backs ambitious companies developing drugs, vaccines, diagnostics, medical devices, and other technologies to address critical global public health challenges. It focuses on historically overlooked market segments, leveraging expertise to translate opportunities into social and financial returns. The firm's investment model is heavily influenced by global trends such as climate change and antimicrobial resistance.
LimmaTech Biologics, Memo Therapeutics, Curevo Vaccine, Antiva Biosciences, Pulmocide, Excision BioTherapeutics, Frontier Nutrition, VitriVax, MinervaX, Evofem, Univercells, YS Biopharma, ChromaCode, 54gene, Codagenix, AN2 Therapeutics, Themis, InDevR, X-Vax
Want more backlinks, traffic, and startup visibility?
Get your startup listed in 100+ directories automatically. Perfect for SaaS, AI, and tech startups.
Submit Your Startup